|Non-ossifying fibroma of tibia|
|Symptoms||Lump, pain, neurological signs, unexplained broken bone, fatigue, fever, weight loss, anemia and nausea. Sometimes no symptoms|
|Types||Noncancerous (benign) or cancerous (malignant)|
|Diagnostic method||Medical imaging, biopsy|
|Prognosis||Varies with type|
A bone tumor is an abnormal growth of tissue in bone, traditionally classified as noncancerous (benign) or cancerous (malignant). Cancerous bone tumors usually originate from a cancer in another part of the body such as from lung, breast, thyroid, kidney and prostate. There may be a lump, pain, or neurological signs from pressure. A bone tumor might present with a pathologic fracture. Other symptoms may include fatigue, fever, weight loss, anemia and nausea. Sometimes there are no symptoms and the tumour is found when investigating another problem.
Diagnosis is generally by X-ray and other radiological tests such as CT scan, MRI, PET scan and bone scintigraphy. Blood tests might include a complete blood count, inflammatory markers, serum electrophoresis, PSA, kidney function and liver function. Urine may be tested for Bence Jones protein. For confirmation of diagnosis, a biopsy for histological evaluation might be required.
The most common bone tumor is a non-ossifying fibroma. Average five-year survival in the United States after being diagnosed with bone and joint cancer is 67%. The earliest known bone tumor was an osteosarcoma in a foot bone discovered in South Africa, between 1.6 and 1.8 million years ago.
Bone tumors are traditionally classified as noncancerous (benign) or cancerous (malignant). Several features of bone tumors and soft tissue tumors overlap. Their classification was revised by the World Health Organization (WHO) in 2020. This newer classification categorises bone tumors into cartilage tumors, osteogenic tumors, fibrogenic tumors, vascular tumors of bone, osteoclastic giant cell-rich tumors, notochordal tumors, other mesenchymal tumors of bone, and hematopoietic neoplasms of bone.
Bone tumors may be classified as "primary tumors", which originate in bone or from bone-derived cells and tissues, and "secondary tumors" which originate in other sites and spread (metastasize) to the skeleton. Carcinomas of the prostate, breasts, lungs, thyroid, and kidneys are the carcinomas that most commonly metastasize to bone. Secondary malignant bone tumors are estimated to be 50 to 100 times as common as primary bone cancers.
Primary bone tumors
Primary tumors of bone can be divided into benign tumors and cancers. Common benign bone tumors may be neoplastic, developmental, traumatic, infectious, or inflammatory in etiology. Some benign tumors are not true neoplasms, but rather, represent hamartomas, namely the osteochondroma. The most common locations for many primary tumors, both benign and malignant include the distal femur and proximal tibia (around the knee joint). Examples of benign bone tumors include osteoma, osteoid osteoma, osteochondroma, osteoblastoma, enchondroma, giant cell tumor of bone and aneurysmal bone cyst.
Malignant primary bone tumors include osteosarcoma, chondrosarcoma, Ewing's sarcoma, fibrosarcoma, and other types. While malignant fibrous histiocytoma (MFH) - now generally called "pleomorphic undifferentiated sarcoma" - primary in bone is known to occur occasionally, current paradigms tend to consider MFH a wastebasket diagnosis, and the current trend is toward using specialized studies (i.e. genetic and immunohistochemical tests) to classify these undifferentiated tumors into other tumor classes. Multiple myeloma is a hematologic cancer, originating in the bone marrow, which also frequently presents as one or more bone lesions.
Secondary bone tumors
Secondary bone tumors are metastatic lesions which have spread from other organs, most commonly carcinomas of the breast, lung, and prostate. Rarely, primary bone malignancies such as osteosarcoma may also spread to other bones. Reliable and valid statistics on the incidence, prevalence, and mortality of malignant bone tumours are difficult to come by, particularly in older adults (those over 75 years of age) - because carcinomas that are widely metastatic to bone are rarely ever curable. Biopsies to determine the origin of the tumour in cases like this are rarely done.
Signs and symptoms
There may be a lump, with or without pain. Pain may increase with the growth of the tumor and may be worse at night and at rest. A bone tumor might present with an unexplained broken bone; with little or no trauma. Additional symptoms may include fatigue, fever, weight loss, anemia and nausea. If the tumor presses a nerve, neurological signs may be present. Sometimes there are no symptoms and the tumour is found when investigating another problem.
A bone tumour may be felt on examination, following which a plain X-ray is usually carried out. Blood tests might include a complete blood count, inflammatory markers, serum electrophoresis, PSA, kidney function and liver function. Urine may be sent for Bence Jones protein. Other tests that might be requested include a CT scan, MRI, PET scan and bone scintigraphy. For confirmation of diagnosis, a biopsy for histological evaluation might be required, using either a needle or by incision (open biopsy).
Treatment of bone tumors is dependent on the type of tumor. Where available, people with bone tumors are treated at a specialist centre which have surgeons, radiologists, pathologists, oncologists and other support staff. Generally, noncancerous bone tumors may be observed for changes and surgery offered if there is pain or pressure effects on neighbouring body parts. Surgical resection with or without cytotoxic drugs may be considered.
Chemotherapy and radiotherapy
Chemotherapy and radiotherapy are effective in some tumors (such as Ewing's sarcoma) but less so in others (such as chondrosarcoma). There is a variety of chemotherapy treatment protocols for bone tumors. The protocol with the best-reported survival in children and adults is an intra-arterial protocol where tumor response is tracked by serial arteriogram. When tumor response has reached >90% necrosis surgical intervention is planned.
One of the major concerns is bone density and bone loss. Non-hormonal bisphosphonates increase bone strength and are available as once-a-week prescription pills. Metastron also known as strontium-89 chloride is an intravenous medication given to help with the pain and can be given in three-month intervals. Generic Strontium Chloride Sr-89 Injection UPS, manufactured by Bio-Nucleonics Inc., it is the generic version of Metastron.
Treatment for some bone cancers may involve surgery, such as limb amputation, or limb sparing surgery (often in combination with chemotherapy and radiation therapy). Limb sparing surgery, or limb salvage surgery, means the limb is spared from amputation. Instead of amputation, the affected bone is removed and replaced in one of two ways: (a) bone graft, in which bone is taken from elsewhere on the body or (b) artificial bone is put in. In upper leg surgeries, limb salvage prostheses are available.
There are other joint preservation surgical reconstruction options, which including allograft, tumor-devitalized autograft, vascularized fibula graft, distraction osteogenesis, and custom-made implants. An analysis of massive knee replacements after resection of primary bone tumours showed patients did not score as highly on the Musculoskeletal Tumour Society Score and Knee Society Score as patients who had undergone intra-articular resection.
Thermal ablation techniques
Over the past two decades, CT guided radiofrequency ablation has emerged as a less invasive alternative to surgical resection in the care of benign bone tumors, most notably osteoid osteomas. In this technique, which can be performed under conscious sedation, a RF probe is introduced into the tumor nidus through a cannulated needle under CT guidance and heat is applied locally to destroy tumor cells. Since the procedure was first introduced for the treatment of osteoid osteomas in the early 1990s, it has been shown in numerous studies to be less invasive and expensive, to result in less bone destruction and to have equivalent safety and efficacy to surgical techniques, with 66 to 96% of patients reporting freedom from symptoms. While initial success rates with RFA are high, symptom recurrence after RFA treatment has been reported, with some studies demonstrating a recurrence rate similar to that of surgical treatment.
Thermal ablation techniques are also increasingly being used in the palliative treatment of painful metastatic bone disease. Currently, external beam radiation therapy is the standard of care for patients with localized bone pain due to metastatic disease. Although the majority of patients experience complete or partial relief of pain following radiation therapy, the effect is not immediate and has been shown in some studies to be transient in more than half of patients. For patients who are not eligible or do not respond to traditional therapies ( i.e. radiation therapy, chemotherapy, palliative surgery, bisphosphonates or analgesic medications), thermal ablation techniques have been explored as alternatives for pain reduction. Several multi-center clinical trials studying the efficacy of RFA in the treatment of moderate to severe pain in patients with metastatic bone disease have shown significant decreases in patient reported pain after treatment. These studies are limited however to patients with one or two metastatic sites; pain from multiple tumors can be difficult to localize for directed therapy. More recently, cryoablation has also been explored as a potentially effective alternative as the area of destruction created by this technique can be monitored more effectively by CT than RFA, a potential advantage when treating tumors adjacent to critical structures.
The outlook depends on the type of tumor. The outcome is expected to be good for people with noncancerous (benign) tumors, although some types of benign tumors may eventually become cancerous (malignant). With malignant bone tumors that have not spread, most patients achieve a cure, but the cure rate depends on the type of cancer, location, size, and other factors.
Bone tumors that originate from bone are very rare and account for around 0.2% of all tumors. Average five-year survival in the United States after being diagnosed with bone and joint cancer is 67%.
The earliest known bone tumor was an osteosarcoma in a foot bone belonging to a person who died in Swartkrans Cave, South Africa, between 1.6 and 1.8 million years ago.
Bones are a common site for tumors in cats and dogs.
- Maruthainar N, Bhumbra R, Cannon S (2018). "7. Orthopaedic oncology". In Ramachandran M (ed.). Basic Orthopaedic Sciences (2nd ed.). CRC Press. pp. 105–121. ISBN 978-1-4441-2098-1.
- "Bone Tumor - Types and Treatments - OrthoInfo - AAOS". www.orthoinfo.org. Retrieved 27 June 2021.
- "Questions and Answers about Bone Cancer" (PDF). Centers for Disease Control and Prevention. Retrieved 27 June 2021.
- Soft Tissue and Bone Tumours: WHO Classification of Tumours. International Agency for Research on Cancer. 2020. pp. 338–344. ISBN 978-92-832-4502-5.
- "SEER Stat Fact Sheets: Bone and Joint Cancer". NCI. Retrieved 18 June 2014.
- Strauss, Mark (28 July 2016). "Earliest Human Cancer Found in 1.7-Million-Year-Old Bone". Culture. Retrieved 27 June 2021.
- Choi JH, Ro JY (May 2021). "The 2020 WHO Classification of Tumors of Bone: An Updated Review". Advances in Anatomic Pathology. 28 (3): 119–138. doi:10.1097/PAP.0000000000000293. PMID 33480599. S2CID 231679037.
- Anderson WJ, Doyle LA (April 2021). "Updates from the 2020 World Health Organization Classification of Soft Tissue and Bone Tumours". Histopathology. 78 (5): 644–657. doi:10.1111/his.14265. PMID 33438273. S2CID 231595171.
- Jeon DG, Song WS, Kong CB, Kim JR, Lee SY. MFH of Bone and Osteosarcoma Show Similar Survival and Chemosensitivity. Clin Orthop Rel Res 469;584-90.
- "Multiple Myeloma". The Lecturio Medical Concept Library. Retrieved 26 August 2021.
- Maoz A, Matsuo K, Ciccone MA, Matsuzaki S, Klar M, Roman LD, et al. (May 2020). "Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cord-Stromal Tumors: A Contemporary Review". Cancers. 12 (6): 1398. doi:10.3390/cancers12061398. PMC 7353025. PMID 32485873.
- "Osteosarcoma". The Lecturio Medical Concept Library. Retrieved 26 August 2021.
- Murali S, Ilaslan H, Holden DM (2015). "2. An imaging approach to bone tumors". In Santini-Araujo E, Kalil RK, Bertoni F, Park YK (eds.). Tumors and Tumor-Like Lesions of Bone: For Surgical Pathologists, Orthopedic Surgeons and Radiologists. Springer. pp. 15–56. ISBN 978-1-4471-6577-4.
- Costelloe CM, Madewell JE (January 2013). "Radiography in the initial diagnosis of primary bone tumors". AJR. American Journal of Roentgenology. 200 (1): 3–7. doi:10.2214/AJR.12.8488. PMID 23255735.
- Bone tumor at Mount Sinai Hospital, New York
- 10 year survival in Pediatric Osteosarcoma
- Survival in Adult Osteosarcoma and MFH of Bone
- "FDA ANDA Generic Drug Approvals". Food and Drug Administration.
- Takeuchi A, Yamamoto N, Hayashi K, Matsubara H, Miwa S, Igarashi K, Tsuchiya H (December 2019). "Joint-preservation surgery for pediatric osteosarcoma of the knee joint". Cancer and Metastasis Reviews. 38 (4): 709–722. doi:10.1007/s10555-019-09835-z. PMID 31807972. S2CID 208650189.
- Kendall SJ, Singer GC, Briggs TW, Cannon SR (September 2000). "A functional analysis of massive knee replacement after extra-articular resections of primary bone tumors". The Journal of Arthroplasty. 15 (6): 754–760. doi:10.1054/arth.2000.8104. PMID 11021451.
- Rosenthal DI, Alexander A, Rosenberg AE, Springfield D (April 1992). "Ablation of osteoid osteomas with a percutaneously placed electrode: a new procedure". Radiology. 183 (1): 29–33. doi:10.1148/radiology.183.1.1549690. PMID 1549690.[permanent dead link]
- Rimondi E, Mavrogenis AF, Rossi G, Ciminari R, Malaguti C, Tranfaglia C, et al. (January 2012). "Radiofrequency ablation for non-spinal osteoid osteomas in 557 patients". European Radiology. 22 (1): 181–188. doi:10.1007/s00330-011-2240-1. PMID 21842430. S2CID 21047698.
- Rosenthal DI, Hornicek FJ, Torriani M, Gebhardt MC, Mankin HJ (October 2003). "Osteoid osteoma: percutaneous treatment with radiofrequency energy". Radiology. 229 (1): 171–175. doi:10.1148/radiol.2291021053. PMID 12944597.[permanent dead link]
- Weber MA, Sprengel SD, Omlor GW, Lehner B, Wiedenhöfer B, Kauczor HU, Rehnitz C (July 2015). "Clinical long-term outcome, technical success, and cost analysis of radiofrequency ablation for the treatment of osteoblastomas and spinal osteoid osteomas in comparison to open surgical resection". Skeletal Radiology. 44 (7): 981–993. doi:10.1007/s00256-015-2139-z. PMID 25910709. S2CID 21496405.
- Rosenthal DI, Hornicek FJ, Wolfe MW, Jennings LC, Gebhardt MC, Mankin HJ (June 1998). "Percutaneous radiofrequency coagulation of osteoid osteoma compared with operative treatment". The Journal of Bone and Joint Surgery. American Volume. 80 (6): 815–821. CiteSeerX 10.1.1.1018.5024. doi:10.2106/00004623-199806000-00005. PMID 9655099. S2CID 10709128. Archived from the original on 2016-10-06. Retrieved 2016-08-07.
- Tong D, Gillick L, Hendrickson FR (September 1982). "The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group". Cancer. 50 (5): 893–899. doi:10.1002/1097-0142(19820901)50:5<893::aid-cncr2820500515>3.0.co;2-y. PMID 6178497.
- Dupuy DE, Liu D, Hartfeil D, Hanna L, Blume JD, Ahrar K, et al. (February 2010). "Percutaneous radiofrequency ablation of painful osseous metastases: a multicenter American College of Radiology Imaging Network trial". Cancer. 116 (4): 989–997. doi:10.1002/cncr.24837. PMC 2819592. PMID 20041484.
- Goetz MP, Callstrom MR, Charboneau JW, Farrell MA, Maus TP, Welch TJ, et al. (January 2004). "Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study". Journal of Clinical Oncology. 22 (2): 300–306. doi:10.1200/JCO.2004.03.097. PMID 14722039.
- Callstrom MR, Dupuy DE, Solomon SB, Beres RA, Littrup PJ, Davis KW, et al. (March 2013). "Percutaneous image-guided cryoablation of painful metastases involving bone: multicenter trial". Cancer. 119 (5): 1033–1041. doi:10.1002/cncr.27793. PMC 5757505. PMID 23065947.
- Dittmer KE, Pemberton S (September 2021). "A Holistic Approach to Bone Tumors in Dogs and Cats: Radiographic and Histologic Correlation". Veterinary Pathology. 58 (5): 841–857. doi:10.1177/0300985821999832. PMID 33779406. S2CID 232409416.